;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Headlines > China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

Headlines

China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

Published by Global Banking and Finance Review

Posted on October 16, 2025

Featured image for article about Headlines

(Reuters) -Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal cancer and other solid tumors.

(Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber)

More from Headlines

Explore more articles in the Headlines category

Sterling tumbles as declining inflation cements BoE cut bets

French drone makers call for more state spending as budget talks drag on

European defence group KNDS plans dual listing in 2026

Domestic demand to drive German recovery in 2026, says IMK

Norway's power grid operators asked to sharpen sabotage preparedness

France's Louvre museum remains shut as workers weigh strike extension

Europe must be responsible for its own security, EU's von der Leyen says

Ukraine drone debris sparks fire at Russia's Slavyansk refinery, authorities say

Volkswagen battery business PowerCo looking more intensively at external funding

TikTok monitored Grindr activity through third-party tracker, privacy group alleges

Agentic AI race by British banks raises new risks for regulator

Analysis-Australia's gun laws riddled with loopholes and workarounds, experts say

View All Headlines Posts